Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application for Vabysmo® for the treatment of macular edema following retinal vein occlusion.
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application for Vabysmo® for the treatment of macular edema following retinal vein occlusion.